{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:01:02Z","timestamp":1780398062878,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04670-z","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:02:06Z","timestamp":1780394526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential effects of dapagliflozin and empagliflozin on skeletal muscle mass in older adults with type 2 diabetes"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-9544","authenticated-orcid":false,"given":"Sencer","family":"Ganidagli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3810-6129","authenticated-orcid":false,"given":"Ey\u00fcp Sami","family":"Akbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-2824","authenticated-orcid":false,"given":"Zeynel Abidin","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"4670_CR1","first-page":"347","volume":"46","author":"AJ Sinclair","year":"2017","unstructured":"A.J. Sinclair, A.H. Abdelhafiz, L. Rodr\u00edguez-Ma\u00f1as, Frailty and sarcopenia\u2014newly emerging and high impact complications of diabetes. Age Ageing. 46, 347\u2013352 (2017)","journal-title":"Age Ageing"},{"key":"4670_CR2","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.2337\/dc12-1801","volume":"35","author":"MS Kirkman","year":"2012","unstructured":"M.S. Kirkman, V.J. Briscoe, N. Clark, Diabetes in older adults. Diabetes Care. 35, 2650\u20132664 (2012)","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"4670_CR3","first-page":"S275","volume":"47","author":"A American Diabetes","year":"2024","unstructured":"A. American Diabetes, Older adults: standards of medical care in diabetes\u20142024. Diabetes Care. 47(Suppl 1), S275\u2013S86 (2024)","journal-title":"Diabetes Care"},{"key":"4670_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"B. Zinman, C. Wanner, J.M. Lachin, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128 (2015)","journal-title":"N. Engl. J. Med."},{"key":"4670_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"S.D. Wiviott, I. Raz, M.P. Bonaca, Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347\u2013357 (2019)","journal-title":"N. Engl. J. Med."},{"key":"4670_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"H.J.L. Heerspink, B.V. Stef\u00e1nsson, R. Correa-Rotter, Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020)","journal-title":"N. Engl. J. Med."},{"key":"4670_CR7","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"M.J. Davies, D.A. D\u2019Alessio, J. Fradkin, Management of hyperglycemia in type 2 diabetes, 2022. Diabetes Care. 45, 2753\u20132786 (2022)","journal-title":"Diabetes Care"},{"issue":"4","key":"4670_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.hfc.2022.03.002","volume":"18","author":"R Pollack","year":"2022","unstructured":"R. Pollack, A. Cahn, SGLT2 Inhibitors and Safety in Older Patients. Heart Fail. Clin. 18(4), 635\u2013643 (2022)","journal-title":"Heart Fail. Clin."},{"key":"4670_CR9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ageing\/afaa132","volume":"50","author":"MMY Lee","year":"2021","unstructured":"M.M.Y. Lee, N. Ghouri, J.J.V. McMurray, SGLT2 inhibitors in older people with diabetes: balancing benefits and risks. Age Ageing. 50, 161\u2013169 (2021)","journal-title":"Age Ageing"},{"key":"4670_CR10","doi-asserted-by":"crossref","unstructured":"D. Emmerton, A. Abdelhafiz, Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people. Hosp Pract (1995). 2021;49(3):164\u2009\u2013\u200975","DOI":"10.1080\/21548331.2021.1905414"},{"issue":"12","key":"4670_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jamda.2014.10.001","volume":"15","author":"JE Morley","year":"2014","unstructured":"J.E. Morley, T.K. Malmstrom, L. Rodriguez-Manas, A.J. Sinclair, Frailty, sarcopenia and diabetes. J. Am. Med. Dir. Assoc. 15(12), 853\u2013859 (2014)","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"4670_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"A. Clegg, J. Young, S. Iliffe, Frailty in elderly people. Lancet. 381, 752\u2013762 (2013)","journal-title":"Lancet"},{"issue":"12","key":"4670_CR13","doi-asserted-by":"publisher","first-page":"e0279889","DOI":"10.1371\/journal.pone.0279889","volume":"17","author":"R Pan","year":"2022","unstructured":"R. Pan, Y. Zhang, R. Wang, Y. Xu, H. Ji, Y. Zhao, Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. PLoS One. 17(12), e0279889 (2022)","journal-title":"PLoS One"},{"issue":"8","key":"4670_CR14","doi-asserted-by":"publisher","first-page":"109068","DOI":"10.1016\/j.jdiacomp.2025.109068","volume":"39","author":"K Miyoshi","year":"2025","unstructured":"K. Miyoshi, T. Aoyama, S. Kameda, N. Ishibashi, Y. Sakai, T. Yamanaka et al., Age different effects of SGLT2 inhibitors on body composition in individuals with type 2 diabetes: A retrospective cohort study. J. Diabetes Complications. 39(8), 109068 (2025)","journal-title":"J. Diabetes Complications"},{"issue":"4","key":"4670_CR15","first-page":"273","volume":"13","author":"C G\u00fcngen","year":"2002","unstructured":"C. G\u00fcngen, T. Ertan, E. Eker, R. Ya\u015far, F. Engin, Reliability and validity of the standardized Mini Mental State Examination in the diagnosis of mild dementia in Turkish population. Turkish J. Psychiatry. 13(4), 273\u2013281 (2002)","journal-title":"Turkish J. Psychiatry"},{"issue":"4","key":"4670_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ageing\/afz046","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"A.J. Cruz-Jentoft, G. Bahat, J. Bauer, Y. Boirie, O. Bruy\u00e8re, T. Cederholm, Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 48(4), 601 (2019)","journal-title":"Age Ageing"},{"issue":"6","key":"4670_CR17","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.clnu.2016.02.002","volume":"35","author":"G Bahat","year":"2016","unstructured":"G. Bahat, A. Tufan, F. Tufan, C. Kilic, T.S. Akpinar, M. Kose, Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. Clin. Nutr. 35(6), 1557\u20131563 (2016)","journal-title":"Clin. Nutr."},{"key":"4670_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.hkpj.2016.07.001","volume":"36","author":"H Parveen","year":"2017","unstructured":"H. Parveen, M.M. Noohu, Evaluation of psychometric properties of Tinetti performance-oriented mobility assessment scale in subjects with knee osteoarthritis. Hong Kong Physiotherapy J. 36, 25\u201332 (2017)","journal-title":"Hong Kong Physiotherapy J."},{"issue":"7","key":"4670_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12603-012-0084-2","volume":"16","author":"JE Morley","year":"2012","unstructured":"J.E. Morley, T.K. Malmstrom, D.K. Miller, A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J. Nutr. Health Aging. 16(7), 601\u2013608 (2012)","journal-title":"J. Nutr. Health Aging"},{"key":"4670_CR20","first-page":"107","volume":"7","author":"MY Agargun","year":"1996","unstructured":"M.Y. Agargun, H. Kara, O. Anlar, The validity and reliability of the Pittsburgh Sleep Quality Index. Turkish J. Psychiatry. 7, 107\u2013115 (1996)","journal-title":"Turkish J. Psychiatry"},{"issue":"6","key":"4670_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jamda.2012.04.012","volume":"13","author":"A Sinclair","year":"2012","unstructured":"A. Sinclair, J.E. Morley, L. Rodriguez-Manas, G. Paolisso, T. Bayer, A. Zeyfang et al., Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J. Am. Med. Dir. Assoc. 13(6), 497\u2013502 (2012)","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"4670_CR22","doi-asserted-by":"publisher","first-page":"106420","DOI":"10.1016\/j.ejim.2025.07.016","volume":"141","author":"C Stollberger","year":"2025","unstructured":"C. Stollberger, J. Finsterer, B. Schneider, Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle. Eur. J. Intern. Med. 141, 106420 (2025)","journal-title":"Eur. J. Intern. Med."},{"key":"4670_CR23","doi-asserted-by":"publisher","first-page":"800490","DOI":"10.3389\/fphar.2022.800490","volume":"13","author":"J Tang","year":"2022","unstructured":"J. Tang, L. Ye, Q. Yan, X. Zhang, L. Wang, Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Front. Pharmacol. 13, 800490 (2022)","journal-title":"Front. Pharmacol."},{"key":"4670_CR24","doi-asserted-by":"publisher","first-page":"1203666","DOI":"10.3389\/fendo.2023.1203666","volume":"14","author":"S Zhang","year":"2023","unstructured":"S. Zhang, Z. Qi, Y. Wang, D. Song, D. Zhu, Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Front. Endocrinol. (Lausanne). 14, 1203666 (2023)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"3","key":"4670_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3945\/ajcn.112.047860","volume":"97","author":"KM Beavers","year":"2013","unstructured":"K.M. Beavers, D.P. Beavers, D.K. Houston, T.B. Harris, T.F. Hue, A. Koster et al., Associations between body composition and gait-speed decline: results from the Health, Aging, and Body Composition study. Am. J. Clin. Nutr. 97(3), 552\u2013560 (2013)","journal-title":"Am. J. Clin. Nutr."},{"issue":"5","key":"4670_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1532-5415.2011.03336.x","volume":"59","author":"LJ Viccaro","year":"2011","unstructured":"L.J. Viccaro, S. Perera, S.A. Studenski, Is timed up and go better than gait speed in predicting health, function, and falls in older adults? J. Am. Geriatr. Soc. 59(5), 887\u2013892 (2011)","journal-title":"J. Am. Geriatr. Soc."},{"issue":"9","key":"4670_CR27","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00125-024-06190-9","volume":"67","author":"LM Gudemann","year":"2024","unstructured":"L.M. Gudemann, K.G. Young, N.J.M. Thomas, R. Hopkins, R. Challen, A.G. Jones et al., Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. Diabetologia. 67(9), 1817\u20131827 (2024)","journal-title":"Diabetologia"},{"issue":"12","key":"4670_CR28","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/dom.15249","volume":"25","author":"D Yabe","year":"2023","unstructured":"D. Yabe, K. Shiki, G. Homma, T. Meinicke, Y. Ogura, Y. Seino et al., Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (>\/=65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes. Metab. 25(12), 3538\u20133548 (2023)","journal-title":"Diabetes Obes. Metab."},{"key":"4670_CR29","doi-asserted-by":"publisher","first-page":"112430","DOI":"10.1016\/j.diabres.2025.112430","volume":"229","author":"T Sarabhai","year":"2025","unstructured":"T. Sarabhai, R. Zingel, J. Bohlken, K. Kostev, Association between SGLT2 inhibitor therapy and prolonged dementia-free survival in older adults with type 2 diabetes: a retrospective cohort study from Germany. Diabetes Res. Clin. Pract. 229, 112430 (2025)","journal-title":"Diabetes Res. Clin. Pract."},{"key":"4670_CR30","doi-asserted-by":"publisher","first-page":"106065","DOI":"10.1016\/j.archger.2025.106065","volume":"141","author":"Z Zhong","year":"2026","unstructured":"Z. Zhong, S. Zhao, W. He, R. Li, S. Xia, SGLT2 inhibitors versus DPP-4 inhibitors and dementia risk in type 2 diabetes: A meta-analysis of cohort studies. Arch. Gerontol. Geriatr. 141, 106065 (2026)","journal-title":"Arch. Gerontol. Geriatr."},{"key":"4670_CR31","doi-asserted-by":"publisher","first-page":"112319","DOI":"10.1016\/j.diabres.2025.112319","volume":"226","author":"BG Yavuz Veizi","year":"2025","unstructured":"B.G. Yavuz Veizi, S.K. Demircan, Biphasic effects of SGLT-2 inhibitors on sleep quality in older people with type 2 diabetes: A longitudinal analysis. Diabetes Res. Clin. Pract. 226, 112319 (2025)","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"4670_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s40001-025-02871-2","volume":"30","author":"A Mansour","year":"2025","unstructured":"A. Mansour, A. Dehghan Najm Abadi, F. Etesam, S. Danaei, Y. Abaszadeh, F. Torabi et al., Association of antidiabetic medications with psychiatric disorders in patients with type 2 diabetes: a cross-sectional study. Eur. J. Med. Res. 30(1), 654 (2025)","journal-title":"Eur. J. Med. Res."},{"issue":"19","key":"4670_CR33","first-page":"1460","volume":"145","author":"BL Neuen","year":"2022","unstructured":"B.L. Neuen, M. Oshima, R. Agarwal, C. Arnott, D.Z. Cherney, R. Edwards et al., Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized. Controlled Trials Circulation. 145(19), 1460\u20131470 (2022)","journal-title":"Controlled Trials Circulation"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04670-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04670-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04670-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:02:09Z","timestamp":1780394529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04670-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4670"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04670-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethic approval was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"199"}}